Intracoronary Compared With Intravenous Bolus Abciximab Application During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: Cardiac Magnetic Resonance Substudy of the AIDA STEMI Trial

Conclusions:
This largest multicenter CMR study in ST-segment elevation myocardial infarction patients to date demonstrates no benefit of intracoronary versus intravenous abciximab administration on myocardial damage and/or reperfusion injury. Infarct size determined by CMR was significantly associated with major adverse cardiac events. (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction [AIDA STEMI]; NCT00712101)

Source: Journal of the American College of Cardiology - March 4, 2013 Category: Cardiology Authors: Ingo Eitel, Jochen Wöhrle, Henning Suenkel, Josephine Meissner, Sebastian Kerber, Bernward Lauer, Matthias Pauschinger, Ralf Birkemeyer, Christoph Axthelm, Rainer Zimmermann, Petra Neuhaus, Oana Brosteanu, Suzanne de Waha, Steffen Desch, Matthias Gutberl Tags: EXPEDITED PUBLICATIONS Source Type: research